Lipocine completes enrollment of lpcn 1148 phase 2 study for decompensated cirrhosis

Top-line 24-week results from proof-of-concept study expected mid-2023 salt lake city , dec. 19, 2022 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system ("cns") disorders by leveraging its proprietary platform to develop differentiated products, today announced that it has completed enrollment in its phase 2 proof-of-concept ("poc") study evaluating the therapeutic potential of lpcn 1148 for the management of decompensated cirrhosis of various etiologies. lipocine intends to explore partnering lpcn 1148.
LPCN Ratings Summary
LPCN Quant Ranking